Nov 06, 2018
FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis
Oct 31, 2018
Sanofi Q3 2018 Performance Confirms Return to Growth
Oct 31, 2018
Atopic Dermatitis Drugs Market Size Worth $6.41 Billion by 2022: Grand View Research, Inc.
Oct 26, 2018
Regeneron Ranked #1 Biopharma Employer for Sixth Time by Science Magazine
Oct 25, 2018
EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
Oct 19, 2018
FDA Approves Asthma Indication for Dupixent® (dupilumab)
Oct 16, 2018
Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
Oct 08, 2018
Libtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation
Sep 28, 2018
FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Sep 28, 2018
Taiho Oncology Presents Real-World Adherence Data for LONSURF® (trifluridine and tipiracil) in Metastatic Colorectal Cancer at ASCO Quality of Care Symposium
Sep 15, 2018
Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis
Sep 13, 2018
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
Sep 12, 2018
FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
Sep 12, 2018
FDA to Review Supplemental Biologics License Application for Praluent® (alirocumab)Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events
Aug 29, 2018
Lower Cholesterol Treatment Breakthrough
Aug 17, 2018
FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
Aug 16, 2018
Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
Aug 13, 2018
Regeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration
Aug 06, 2018
Regeneron and bluebird bio Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer
Aug 03, 2018
Regeneron Announces the 2018 Winners of the Regeneron Prize for Creative Innovation